The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical device company PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development
  • Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations
  • He will focus on quickly growing a research and development team to capture and commercialise the many business developments and new product opportunities
  • On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share

PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development.

Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations.

Previously, he has worked as product development manager, operations director, research and development director and Chief Technology Officer at SDI, a medical devices company that specialises in manufacturing dental materials.

Joshua will focus on quickly growing a research and development team to
capture and commercialise the many business developments and new product opportunities.

His role is to lead the innovation strategy and research and development activities and to develop the future product portfolio for PolyNovo.

“This is a very exciting and significant appointment that will spearhead the
building of a world-class research and development team befitting the company’s market capitalisation,” Chairman David Williams said.

Managing Director Paul Brennan says the company will continue to invest in the expansion of its research and development team.

“Joshua will be recruiting additional scientists to bolster the team and accelerate our pipeline of new products,” he added.

On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share.

PNV by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…